Keyphrases
Adverse Events
12%
American Psychiatric Association
12%
Body Mass Index
12%
Brief Psychiatric Rating Scale
37%
Change from Baseline
12%
Clinical Trial Registry
12%
Clinically Significant Change
12%
Completed Suicide
12%
Corrected QT
12%
DSM-IV
12%
Early Termination
12%
Extrapyramidal Disorders
12%
Flexible Dose
12%
Fridericia
12%
Index Measure
12%
Intent-to-treat Analysis
12%
Interim Analysis
12%
Laboratory Measures
25%
Last Observation Carried Forward
12%
Least Mean Square
12%
Long-term Efficacy
12%
Long-term Safety
12%
Long-term Tolerability
12%
Mass Movement
12%
Metabolic Indices
12%
Metabolic Profiling
12%
Movement Disorders
12%
Multicenter Trial
12%
Open-label Extension
100%
Per-protocol Analysis
12%
Placebo
50%
Placebo-controlled
100%
QTcF
12%
Randomized Double-blind
12%
Safety Assessment
12%
Safety Self-efficacy
12%
Schizophrenia
100%
Schizophrenia Treatment
12%
Somnolence
25%
Statistical Manual of Mental Disorders
12%
Treatment-related Adverse Events
12%
Vital Signs
12%
Ziprasidone
100%
Medicine and Dentistry
Adolescent
100%
Adverse Event
25%
Body Mass Index
12%
Brief Psychiatric Rating Scale
37%
Clinical Trial
12%
Diagnostic and Statistical Manual of Mental Disorders
12%
DSM-IV
12%
Electrocardiogram
12%
Extrapyramidal Syndrome
12%
Intention-to-Treat Analysis
12%
Interim Analysis
12%
Least Square Analysis
12%
Placebo
100%
Randomized Controlled Trial
87%
Safety Assessment
12%
Somnolence
25%
Stereotypic Movement Disorder
12%
Treatment of Schizophrenia
12%
Vital Sign
12%
Ziprasidone
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Clinical Trial
12%
Diagnostic and Statistical Manual of Mental Disorders
12%
DSM-IV
12%
Extrapyramidal Syndrome
12%
Motor Dysfunction
12%
Placebo
100%
Randomized Controlled Trial
87%
Safety Assessment
12%
Somnolence
25%
Tolerability
12%
Ziprasidone
100%